Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) EBIT Margin (2020 - 2025)

Fennec Pharmaceuticals filings provide 4 years of EBIT Margin readings, the most recent being 16.06% for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 2785.0% to 16.06% in Q4 2025 year-over-year; TTM through Dec 2025 was 3.4%, a 880.0% decrease, with the full-year FY2025 number at 3.39%, down 880.0% from a year prior.
  • EBIT Margin hit 16.06% in Q4 2025 for Fennec Pharmaceuticals, up from 1.52% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 54.16% in Q1 2024 to a low of 314.25% in Q1 2023.
  • Median EBIT Margin over the past 3 years was 17.14% (2023), compared with a mean of 51.12%.
  • Biggest five-year swings in EBIT Margin: soared 36841bps in 2024 and later tumbled -6339bps in 2025.
  • Fennec Pharmaceuticals' EBIT Margin stood at 18.67% in 2023, then soared by 37bps to 11.79% in 2024, then surged by 236bps to 16.06% in 2025.
  • The last three reported values for EBIT Margin were 16.06% (Q4 2025), 1.52% (Q3 2025), and 28.31% (Q2 2025) per Business Quant data.